Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma announced that data from two of its clinical studies will be presented at the 2025 ASCO Annual Meeting, a prominent event in the oncology field. The presentations will feature results from studies on lisaftoclax and alrizomadlin, highlighting the company’s advancements in cancer treatment and potentially enhancing its position in the oncology market.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancer, hepatitis B, and age-related diseases. The company specializes in apoptosis-targeted drugs, with key products including Bcl-2 selective inhibitors and MDM2-p53 inhibitors.
YTD Price Performance: -5.61%
Average Trading Volume: 4,433,082
Technical Sentiment Signal: Sell
Current Market Cap: HK$14.81B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.